2 tablets of: L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg

Dyslipidemias

Cardiovascular Risk Factor

Oral administration of 2 tablets of atorvastatin 10 mg (each one) every 24 hours for 6 months.

L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg

Oral administration of 2 tablets atorvastatin 10 mg (each one) every 24 hours for 6 months.

Atorvastatin 10mg

World Health Organization: Global Status report on non-communicable diseases 2014.

Diagnostic and Treatments od the Dyslipidemias (Hypercholesterolemia) in adults. México, 2016.

Protocolo clínico para el diagnóstico y tratamiento de las Dislipidemias. CENAPRECE, Secretaría e Salud, D.F. México.

Treatment of lipids (including hypercholesterolemia) in secondary prevention.

Detección y Estratificación de Factores de Riesgo Cardiovascular. México, 2010.

Organization for Economic Cooperation and Development.

Laboratorios Grossman Sa

Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population

Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina

Evaluate the change of atorvastatin + l-carnitine vs. atorvastatin alone for dyslipidemia, through change of C-LDL in mg/dl

Evaluate the change of Cholesterol no-HDL in Mexican adults with dyslipidemia through the use of oral route L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment.

Evaluate the change of serum levels of Cholesterol in mg/dl in Mexican adults with dyslipidemia through the use of oral route L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment.

Evaluate the reduction of serum levels of Triglycerides in mg/dl in Mexican adults with dyslipidemia through the use of oral route L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment

Evaluate the change of serum levels of Cholesterol HDL in mg/dl in Mexican adults with dyslipidemia through the use of oral route L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment

Evaluate the incidence, of serious and non-serious adverse events related through the oral route administration of L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment in the subjects participating in the study

porphyrias/protease

Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population

המאגר השלם ביותר של צמחי מרפא המגובה על ידי המדע